Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.
Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York; Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.
J Am Coll Cardiol. 2017 Oct 3;70(14):1777-1784. doi: 10.1016/j.jacc.2017.08.038.
The clinical use of ivabradine has and continues to evolve along channels that are predicated on its mechanism of action. It selectively inhibits the funny current (I) in sinoatrial nodal tissue, resulting in a decrease in the rate of diastolic depolarization and, consequently, the heart rate, a mechanism that is distinct from those of other negative chronotropic agents. Thus, it has been evaluated and is used in select patients with systolic heart failure and chronic stable angina without clinically significant adverse effects. Although not approved for other indications, ivabradine has also shown promise in the management of inappropriate sinus tachycardia. Here, the authors review the mechanism of action of ivabradine and salient studies that have led to its current clinical indications and use.
依伐布雷定的临床应用一直在发展,其作用机制是其发展的基础。它选择性地抑制窦房结组织中的内向整流钾电流(I f ),导致舒张期去极化速率降低,从而降低心率,这一机制有别于其他负性变时药物。因此,它已被评估并用于患有射血分数降低的心力衰竭和慢性稳定性心绞痛的患者,且没有临床意义上的不良影响。尽管尚未批准用于其他适应证,但依伐布雷定在不适当窦性心动过速的治疗中也显示出良好的效果。本文作者回顾了依伐布雷定的作用机制以及导致其目前临床适应证和应用的重要研究。